UK glyphosate controversy

What happened: On April 21, Robert F. Kennedy Jr., the Health and Human Services Secretary, testified before senators that glyphosate, a key ingredient in herbicides like Roundup, causes cancer. This claim is based on studies showing glyphosate's carcinogenic properties. The use of glyphosate in the UK has been controversial, with Scottish farmers pioneering its use in the 1980s to accelerate wheat drying before harvest. The Make America Healthy Again (MAHA) movement, allied with Republicans, faces a significant test this week as the Supreme Court hears a case on glyphosate's preemption of state laws, and a bill moves through Congress addressing the issue.

Market impact: The glyphosate controversy is driving uncertainty in the agricultural sector, particularly for companies like Bayer, which acquired Roundup's manufacturer, Monsanto. If glyphosate's use is restricted or banned, it could disrupt supply chains and impact crop yields. Investors are watching for regulatory changes that could affect these companies' valuations. Farmers and consumers may also face higher costs due to potential glyphosate alternatives.

What to watch next: On April 25, the Supreme Court will hear the glyphosate preemption case, which could set a precedent for state-level regulations. Additionally, the progress of the bill moving through Congress will be closely watched, as it could impose federal restrictions on glyphosate. Bayer's upcoming earnings report (May 4) may provide insights into how the company is managing the glyphosate controversy.